S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

$0.90
+0.05 (+5.91%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.83
▼
$0.90
50-Day Range
$0.72
▼
$1.48
52-Week Range
$0.72
▼
$2.12
Volume
127,882 shs
Average Volume
1.31 million shs
Market Capitalization
$73.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Pieris Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
0.14mentions of Pieris Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$8,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

484th out of 983 stocks

Pharmaceutical Preparations Industry

233rd out of 486 stocks

See Top Rated MarketRank™ Stocks Here

PIRS stock logo

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

June 2, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 2, 2023 | finance.yahoo.com
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 4, 2023 | Stocks To Trade (Ad)
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
May 22, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 21, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 17, 2023 | americanbankingnews.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to Post Q2 2023 Earnings of ($0.16) Per Share, William Blair Forecasts
May 15, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially
May 12, 2023 | seekingalpha.com
Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57M
June 4, 2023 | Legacy Research (Affiliate) (Ad)
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
May 11, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript
May 10, 2023 | msn.com
Recap: Pieris Pharmaceuticals Q1 Earnings
May 10, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 10, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 9, 2023 | msn.com
Preview: Pieris Pharmaceuticals's Earnings
May 8, 2023 | americanbankingnews.com
Pieris Pharmaceuticals (PIRS) to Release Quarterly Earnings on Tuesday
May 5, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business
May 4, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep
May 4, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 2, 2023 | finance.yahoo.com
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
April 17, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual Meeting
April 17, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
April 5, 2023 | americanbankingnews.com
William Blair Comments on Pieris Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:PIRS)
April 4, 2023 | americanbankingnews.com
Pieris Pharmaceuticals, Inc. Forecasted to Post Q1 2023 Earnings of ($0.19) Per Share (NASDAQ:PIRS)
April 2, 2023 | americanbankingnews.com
Equities Analysts Set Expectations for Pieris Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:PIRS)
April 1, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript
March 31, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021)
March 31, 2023 | americanbankingnews.com
Jefferies Financial Group Comments on Pieris Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:PIRS)
See More Headlines

PIRS Price History

PIRS Company Calendar

Last Earnings
3/29/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
CUSIP
N/A
CIK
1583648
Web
www.pieris.com
Phone
(857) 246-8998
Fax
49-8161-141-1444
Employees
124
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,280,000.00
Net Margins
-245.45%
Pretax Margin
-245.45%
Return on Equity
-133.94%
Return on Assets
-42.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.41
Quick Ratio
1.41

Sales & Book Value

Annual Sales
$16.85 million
Price / Sales
4.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
4.71

Miscellaneous

Outstanding Shares
82,019,000
Free Float
76,032,000
Market Cap
$73.45 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Stephen S. Yoder
    President, Chief Executive Officer & Director
  • Thomas Bures
    Senior VP, Chief Financial & Accounting Officer
  • Kayti Aviano
    Vice President-Clinical Operations
  • Hitto Kaufmann
    Chief Scientific Officer & Senior Vice President
  • Shane OlwillShane Olwill
    Chief Development Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2023?

Pieris Pharmaceuticals' stock was trading at $1.04 at the beginning of the year. Since then, PIRS stock has decreased by 13.9% and is now trading at $0.8955.
View the best growth stocks for 2023 here.

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PIRS earnings forecast.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings data on Wednesday, March, 29th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $5.85 million during the quarter, compared to analyst estimates of $6.51 million. Pieris Pharmaceuticals had a negative net margin of 245.45% and a negative trailing twelve-month return on equity of 133.94%.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.63%), Platinum Investment Management Ltd. (1.31%), Acadian Asset Management LLC (0.85%), Renaissance Technologies LLC (0.52%), Candriam S.C.A. (0.47%) and Affinity Asset Advisors LLC (0.37%). Insiders that own company stock include Aquilo Capital Management, Llc, Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $0.90.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $73.45 million and generates $16.85 million in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -